Condition category
Cancer
Date applied
30/07/2010
Date assigned
30/07/2010
Last edited
01/03/2016
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Contact information

Type

Scientific

Primary contact

Ms Milena Toncheva

ORCID ID

Contact details

Trial Coordinator - Haematology Trials Group
Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
W1T 4TJ
United Kingdom
-
reveal@ctc.ucl.ac.uk

Additional identifiers

EudraCT number

2009-014906-33

ClinicalTrials.gov number

Protocol/serial number

8441

Study information

Scientific title

A pilot study of relapsed or refractory patients using Velcade™ (bortezomib) combination chemotherapy in AL amyloidosis

Acronym

REVEAL

Study hypothesis

The trial aims to assess the efficacy, safety and tolerability of two bortezomib-based combination chemotherapy regimens in patients with AL amyloidosis who have relapsed (disease has been succesfully treated but has returned) or have inadequate response to front line treatment (disease has responded partly but not enough to improve the amyloid related organ function) or are refractory (disease has not responded at all to prior treatment).

Background:
AL amyloidosis is a multisystem disorder resulting from the accumulation of abnormal protein deposits called amyloid deposits in various organs of the body, causing impairment of organ function. The deposited proteins are formed by light chains secreted by abnormal plasma cells (a type of blood cell). Treatment of AL amyloidosis involves chemotherapy to kill the abnormal plasma cell, thus reducing the abnormal light chains, in the hope of slowing down or halting amyloid deposition, and preserving organ function. Bortezomib, used as a single agent, has been shown to be an effective agent for treating myeloma and amyloidosis and combining it with other drugs appears to increase the rapidity and completeness of response i.e. a quick and long-lasting remission in myeloma. The current study would be the first study of such combinations in relapsed or refractory AL amyloidosis.

Specific aims of research:
The study will compare two bortezomib-dexamethasone-chemotherapy combinations, one with adriamycin (PAD) and one with cyclophosphamide (CVD), in a randomised multicentre parallel phase II design.

Outline of research plan:
The patients will be identified and consented at the UK National Amyloidosis Centre and will be treated at regional haematology centres (RHCs). They will be given 3 cycles of chemotherapy and will be assessed for response thereafter. Those who have only a partial response will continue to a maximum of six cycles.

Ethics approval

Central London REC 4 pending as of 13/08/2010, ref: 10/H0715/30

Study design

Multicentre randomised interventional treatment trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Topic: National Cancer Research Network; Subtopic: Haematological Oncology; Disease: Leukaemia (acute), Leukaemia (acute lymphoblastic)

Intervention

PAD or CVD (maximum of 6 x 21 day cycles):

1. PAD:
Bortezomib 1.0 mg/m2 intravenous (IV) Days 1, 4, 8, 11 (increase to 1.3 mg/m2 if well tolerated)
Doxorubicin 18 mg/m2 IV Days 1, 8
Dexamethasone 20 mg orally (po) Days 1, 4, 8, 11 (increase to 40 mg if well tolerated)

2. CVD:
Bortezomib 1.0 mg/m2 IV Days 1, 4, 8, 11 (increase to 1.3 mg/m2 if well tolerated)
Cyclophosphamide 350 mg/m2 po Days 1, 8, 15
Dexamethasone 20 mg po Days 1, 4, 8, 11 (increase to 40 mg if well tolerated)

Follow-up length: 7 months
Study entry: single randomisation only

Intervention type

Drug

Phase

Phase II

Drug names

Bortezomib, adriamycin, cyclophosphamide

Primary outcome measures

1. Clonal response of the underlying plasma cell dyscrasia
2. Safety and toxicity of PAD and CVD
All assessed at 3 or 7 months.

Secondary outcome measures

1. Improvement in amyloidotic organ function
2. Overall survival
3. Cost effectiveness
All assessed at 7 months.

Overall trial start date

01/12/2010

Overall trial end date

31/05/2013

Reason abandoned

Eligibility

Participant inclusion criteria

1. Aged 18 years or greater, either sex
2. Systemic AL amyloidosis who fulfil all the following criteria:
2.1. Measurable clonal disease in the serum as defined by either a serum paraprotein of greater than 7 g/L or the abnormal component of the serum free light chain greater than 75 mg/L (abnormal ratio only in case of renal failure)
2.2. Amyloid related organ dysfunction or organ syndrome
3. Following prior chemotherapy or prior autologous stem cell transplant, evidence of either:
3.1. Clonal disease relapse
3.2. Refractory clonal disease
3.3. Inadequate clonal response (defined as less than a 90% reduction in serum clonal markers)
4. Capable of providing written informed consent

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned sample size: 52; UK sample size: 52

Participant exclusion criteria

1. Overt symptomatic non-amyloid manifestations of multiple myeloma
2. Amyloidosis of unknown or non-AL type
3. Localised AL amyloidosis (in which amyloid deposits are limited to a typical single organ, for example the bladder or larynx, in association with a clonal proliferative disorder within that organ)
4. Trivial or incidental AL amyloid deposits in the absence of a significant amyloid related organ syndrome (e.g., isolated carpal tunnel syndrome)
5. Allogeneic stem cell transplantation
6. Solid organ transplantation
7. Severe peripheral neuropathy or autonomic neuropathy causing significant functional impairment
8. Thrombocytopaenia (platelet count less than 50 x 10^9/l)
9. Neutropaenia (neutrophil count less than 1 x 10^9/l)
10. Liver involvement by amyloid causing bilirubin greater than 2 times or alkaline phosphatase greater than 4 times upper limit of normal
11. Estimated glomerular filtration rate (eGFR) less than 20 ml/min but not on dialysis (patients on dialysis are not excluded)
12. Ejection fraction less than 40%
13. New York Heart Association (NYHA) class IV heart failure
14. Eastern Cooperative Oncology Group (ECOG) performance status greater than 3
15. Estimated life expectancy of less than 3 months
16. Active hepatitis B or C or human immunodeficiency virus (HIV) infection
17. Previous cumulative anthracycline dose of greater than 200 mg/m2
18. Previous treatment with bortezomib combined with anthracycline and/or alkylator and/or immunomodulatory drugs (ImiD)
19. Concurrent active malignancies, except surgically removed basal cell carcinoma of the skin or other in situ carcinomas
20. Pregnant, lactating or unwilling to use adequate contraception
21. Intolerance/sensitivity to any of the study drugs

Recruitment start date

01/12/2010

Recruitment end date

31/05/2013

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Cancer Research UK & UCL Cancer Trials Centre
London
W1T 4TJ
United Kingdom

Sponsor information

Organisation

University College London (UCL) (UK)

Sponsor details

Gower Street
London
WC1E 6BT
United Kingdom

Sponsor type

University/education

Website

http://www.ucl.ac.uk/

Funders

Funder type

Charity

Funder name

Cancer Research UK (CRUK) (UK) - Clinical Trials Advisory and Awards Committee (CTAAC) grant (ref: C23725/A11440)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

01/03/2016: No publications found, verifying study status with principal investigator